In a study by Wenxia Liu and colleagues (2022), focusing on determining the relationship between fungal infections and inflammation, it was suggested that the synergistic function between azole antifungal agents (CYP51 inhibitors) and nonsteroidal anti‐ınflammatory drugs (NSAIDs; COX‐2 inhibitors) could effectively enhance their therapeutic efficacy in vivo (Figure 41; Liu et al. 2022). This evidence concerns the gene CYP51A1 and fungal infectious disease.